Introduction
A clinically important target for antitumor therapy is hypoxia-inducible factor (HIF), which is associated with resistance to apoptosis, chemotherapy and radiotherapy, and increased invasion/metastasis, angiogenesis and patient mortality. 1, 2 HIF is a transcription factor that is expressed in a wide range of primary tumors, metastases and cancer stem cells, whereas it is undetectable in normal, healthy tissues. [3] [4] [5] Tumor-specific activation of HIF occurs by two mechanisms. First, HIF is activated in response to decreased oxygen (hypoxia) within the tumor mass. 2, 6, 7 Second, HIF is activated under normoxia in tumor cells that have acquired genetic mutations in oncogene and tumor-suppressor gene pathways. 8 The importance of HIF in tumor biology is further highlighted by studies, which show that experimental manipulation of HIF levels in tumor models leads to changes in tumor growth, angiogenesis and metastasis. [9] [10] [11] [12] [13] [14] [15] [16] [17] Furthermore, HIF has a crucial role in the self-renewal, proliferation, survival and tumor initiation potential of cancer stem cells. 5 Consistent with these functional studies, a large number of HIF-regulated genes have crucial roles in promoting tumorigenesis. 18 These findings indicate that drugs, which eradicate HIF-active tumor cells, may be useful antitumor agents. However, identification of HIF inhibitors has encountered major obstacles, as all of the drugs currently developed target pathways, which regulate HIF rather than directly inhibiting HIF. 2 Oncolytic adenoviruses (Ads) are a cancer therapy, which use the cytolytic replication cycle of the virus to specifically kill tumor cells (oncolysis). A wild-type Ad cannot be used for cancer therapy because it lacks tumor specificity and is toxic to normal healthy tissues. A number of genetic engineering strategies have been used to specifically target the Ad cytolytic replication cycle to tumor cells, thereby creating oncolytic Ads. [19] [20] [21] [22] One strategy involves transcriptional regulation of E1A expression, a gene, which is essential for Ad replication. This has been achieved using promoters that are preferentially active in tumors compared with normal tissues. Three oncolytic Ads, dl1520, Ad5-CD/ TKrep and CV706, have shown overall safety and modest antitumor activity in clinical trials. 23 While encouraging, these first-generation oncolytic Ads had deficiencies in their design, which contributed to weak antitumor efficacy in patients. [23] [24] [25] [26] This highlights the need to optimize the design of oncolytic Ads before clinical trial testing.
To specifically target and kill HIF-active tumor cells, we exploit the differential activation of HIF-dependent gene expression in tumors versus normal tissue for the design of HIF-activated oncolytic Ads. In the HIFactivated oncolytic Ad, HYPR-Ad#1, a novel bi-directional HIF-responsive promoter was introduced into the Ad genome for regulated expression of E1A. 27, 28 Infection of tumor cells with HYPR-Ad#1 results in conditional E1A expression, viral replication and tumor cell death under HIF-active conditions. 28 Importantly, HYPRAd#1 replicates in hypoxic regions of tumors in vivo and has antitumor activity resulting in a modest reduction in tumor growth. 29 To increase the anticancer efficacy of HYPR-Ad beyond the killing of HIF-active tumor cells, we armed the virus with the interleukin-4 (IL4) gene. IL4 was chosen because it is a potent multimodal antitumorigenic cytokine. 30 In HYPR-Ad-IL4, the bi-directional HIF promoter is used for the co-regulated expression of E1A and IL4. HYPR-Ad-IL4 shows HIF-dependent E1A and IL4 expression, viral replication and tumor cell lysis. 31 Importantly, HYPR-Ad-IL4 treatment results in rapid and long-lasting tumor regressions, and its antitumor activity is superior to that of HYPRAd#1. Our studies with HYPR-Ad#1 and HYPR-Ad-IL4 provided crucial proof that using an HIF-activated oncolytic Ad to kill HIF-active tumor cells and inhibit tumor growth is a feasible approach. 28, 29, 31 Although promising, these viruses showed decreased viral replication, oncolytic and cellular release activity when compared with a wild-type Ad in vitro. 31 It is important to correct these deficiencies before clinical studies as it affects antitumor potency. The rationale is that increased viral progeny production (replication) and cell-to-cell spread (oncolysis and cellular release) will result in a more potent antitumor response. In this study, we created secondgeneration HIF-activated oncolytic Ads called HIF-Ad and HIF-Ad-IL4, which have two key genetic modifications that dramatically improve their replication, oncolytic and antitumor efficacy compared with the HYPR-Ads. We anticipate that these improvements will translate into increased clinical efficacy and improved survival for cancer patients using oncolytic Ad therapy.
Results
The Ad replication cycle further increases HIF transcriptional activity under hypoxia One potential explanation for the attenuated phenotype of the HYPR-Ads is an inhibition of the HIF pathway during the Ad replication cycle. 32, 33 Indeed, a large number of cellular pathways are dysregulated during the Ad replication cycle. 34 Therefore, we evaluated if HIF transcriptional activity was modulated under normoxia or hypoxia after infection with a wild-type Ad in LN229 ( Figure 1a ) and U251MG-T2 (Figure 1b) cells. For this, cells were transfected with a plasmid containing the luciferase reporter gene under the control of the same HIF-responsive promoter, which is present in the HYPRAds. As expected, 27 in mock-infected cells there was a hypoxia-dependent increase in the expression of the luciferase reporter gene (Po0.006). In virus-infected cells maintained under normoxia, the overall levels of HIF transcriptional activity remained relatively constant compared with that in the mock-infected cells (P40. 46 ). An exception was a slight, but significant, 1.5-fold increase in HIF transcriptional activity in LN229 cells at multiplicity of infection (MOI) 25 (P ¼ 0.013). In virus-infected cells maintained under hypoxia, there was a dose-dependent increase in HIF transcriptional activity after virus infection compared with mock-infected controls (Po0.013). These results show that the Ad replication cycle further increases HIF transcriptional activity under hypoxia rather than inhibiting its activity. Therefore, we sought an alternative explanation for the reduced replication and oncolytic activity of the HYPRAds compared with a wild-type Ad.
Construction of genetically modified HYPR-Ads: HIF-Ad and HIF-Ad-IL4
We next evaluated whether genetic modifications to the HYPR-Ad genome would result in improved therapeutic efficacy. For this, we constructed genetically modified viruses called HIF-Ad and HIF-Ad-IL4, which have two important modifications compared with the HYPR-Ads: (i) substitution of a CMV-for a more efficient E1A-minimal promoter sequence in the right arm of the bidirectional HIF-promoter used to regulate E1A gene expression and (ii) insertion of the Ad E3 gene region ( Figure 2a) . In HIF-Ad-IL4, the IL4 adjuvant therapeutic gene was introduced into the left arm of the HIF promoter. The HYPR-Ads contain a bi-directional HIFresponsive promoter, which consists of two genetically identical CMV minimal promoters that have the potential to form an inverted DNA repeat. 27, 28, 31 These repeats are associated with the formation of highly stable secondary structures, such as a cruciform or hairpin, which block DNA synthesis (reviewed by Kramer et al., 35 Lobachev et al., 36 Bissler 37 ). Therefore, substituting an HRE-E1A promoter for one of the HRE-CMV promoters should allow us to circumvent this potential issue and lead to improved virus replication. The HYPR-Ads also have a deletion of the E3 gene region. 28, 31 The E3 region encodes the Adenovirus Death Protein (ADP) gene, which has a key role in host cell lysis and viral release at the completion of the Ad replication cycle. 38 Ads that lack ADP show impaired virus release, delayed cytolysis, slower cell-to-cell spread and reduced antitumor activity compared with Ads that retain the ADP gene. 38, 39 Therefore, inclusion of E3 in the HIF-Ads should lead to improved oncolysis and viral release. In the sections below, we directly compare the therapeutic efficacy of the HIF-Ads versus the HYPR-Ads.
Hypoxia-dependent E1A and IL4 expression by HIF-Ad and HIF-Ad-IL4
Hypoxia-dependent regulation of the bi-directional HIFresponsive promoter within HIF-Ad and HIF-Ad-IL4 was examined by measuring E1A and IL4 protein expression under normoxia versus hypoxia. E1A expression was detected by western blot analysis using infected LN229 (Figure 2b ) and Daoy (Supplementary Figure S1a) cell lysates. Mock-infected cells served as negative control and showed no expression of E1A. Cells infected with Ad5WT, a wild-type Ad that lacks tumor specificity and is not hypoxia-regulated, showed similar levels of E1A expression under normoxia and hypoxia. By contrast, HIF-Ad and HIF-Ad-IL4 showed hypoxiadependent E1A expression. Consistent with published Improved HIF-activated oncolytic adenoviruses T Cherry et al studies, 31 HYPR-Ad#1 and HYPR-Ad-IL4 also showed hypoxia-dependent E1A expression (Figure 2b ). Of importance, the levels of E1A expression by the HIFAds under hypoxia were comparable to that of Ad5WT, demonstrating the strength of the HIF-responsive promoter.
IL4 expression by HIF-Ad-IL4 was measured by ELISA using conditioned media from virus-infected LN229 (Figures 2c and d) and Daoy (Supplementary Figure S1b) cells. As expected, mock-and HIF-Adinfected negative control samples showed undetectable IL4 levels under normoxia and hypoxia. In contrast to these controls, HIF-Ad-IL4-infected cells showed a significant increase in the amount of IL4 produced under hypoxia versus normoxia. In agreement with published studies, 31 HYPR-Ad-IL4 also showed hypoxia-dependent IL4 expression (Figures 2c and d) . Under hypoxia there was no difference in the amount of IL4 produced in HIFAd-IL4 versus HYPR-Ad-IL4-infected cells at 2 days post infection (dpi) (1.3-fold increase; P ¼ 0.951; Figure 2c ). By contrast, at 4 dpi there was a significant fivefold increase in the amount of IL4 produced under hypoxia by HIFAd-IL4-as compared with HYPR-Ad-IL4-infected cells (Po0.001; Figure 2d ).
In summary, these results show that HIF-Ad and HIFAd-IL4 express E1A and IL4 selectively under hypoxia and that the bi-directional HIF-responsive promoter maintains its proper regulation in the HIF-Ad genome. Figure 1 The Ad replication cycle further increases HIF transcriptional activity under hypoxia rather than inhibiting its activity. LN229 (a) and U251MG-T2 (b) cells were transfected with the pBIGL-V6R plasmid, which contains a luciferase reporter gene under the regulation of an HIF-responsive promoter. Cells were then infected with a wild-type Ad (dl309-Ad) at the indicated MOI and incubated under normoxia versus hypoxia. The next day luciferase activity was measured and normalized to total cellular protein levels (light units/mg protein). The data represent the mean±s.d. The HIF-Ads have potent antitumor activity, which is superior to the HYPR-Ads
The antitumor efficacy of HIF-Ad and HIF-Ad-IL4 was examined in two independent studies using subcutaneous LN229 tumor xenografts in nu/nu mice (Figures 5a  and b) . In Study-1, tumors were grown to an average size of 92 mm 3 and then treated intratumorally with HIF-Ad-IL4, Ad5WT or phosphate-buffered saline (PBS) ( Figure  5a ). Tumor growth was monitored for 45 days after treatment at which point the PBS-treated tumors showed a 9.5-fold increase in size and tumor burden was reached. By contrast, Ad5WT and HIF-Ad-IL4 treatment led to a dramatic 8.6-to 19-fold reduction in tumor growth, respectively, compared with PBS-treated tumors (Po0.001). Quite striking was the large number of tumors, which exhibited a regression in size after HIFAd-IL4 and Ad5WT treatment (Supplementary Table S1 ). For example, by day 71 of the study (45 days after treatment), there were 9/10, 7/10 and 1/10 tumors, which showed a regression in size after HIF-Ad-IL4, Ad5WT and PBS treatment, respectively. In addition, the magnitude of the tumor regressions was dramatic, with HIF-Ad-IL4-and Ad5WT-treated tumors showing an average 70% regression in size (not shown). Finally, 25  71  64  57  49  43  36  26  56  54  50  46  43  40  37  33  28   35  64  60  57  53  49  46  42  45  73  69  66  62  59 Improved HIF-activated oncolytic adenoviruses T Cherry et al tumor growth inhibition by HIF-Ad-IL4 and Ad5WT treatment was maintained long-term. In Study-2, the antitumor efficacy analysis was expanded to include HIF-Ad treatment and the ability to inhibit the growth of large tumors (Figure 5b ). Tumor xenografts were grown to an average size of 235 mm 3 and then treated intratumorally with HIF-Ad, HIF-Ad-IL4, Ad5WT or PBS. Tumor growth was monitored for 28 days after treatment when animals had to be killed due to the large size of the PBS-treated tumors. During this period, an eightfold increase in tumor size was seen in the PBS treatment group. HIF-Ad and Ad5WT treatment led to a modest twofold reduction in tumor growth compared with PBS-treated tumors (P ¼ 0.045 and P ¼ 0.047, respectively). There was no evidence of tumor regressions in the PBS, HIF-Ad and Ad5WT treatment groups (Supplementary Table S2 ). In striking contrast, all of the tumors treated with HIF-Ad-IL4 (4/4) showed a regression in tumor size by 40-85% (Supplementary Table S2 ). At the end of the study there was a significant 12-fold reduction in tumor growth in the HIF-Ad-IL4 treatment group compared with that in the PBS-treated tumors (P ¼ 0.003). Finally, there were no virus treatment-related deaths or observable toxicity (activity or weight change) in these two animal tumor studies (Supplementary Figure S4a and b) . These data illustrate that HIF-Ad and HIF-Ad-IL4 have potent antitumor activity, which is equal to or greater than that of Ad5WT.
The antitumor efficacy of the HIF-Ads was also compared to that of the HYPR-Ads using subcutaneous LN229 tumor xenografts in nu/nu mice (Figures 5c and d) . In both studies, tumor growth was monitored for approximately 4 weeks after treatment when animals had to be killed due to the large size of the PBS-and HYPR-Ad-treated tumors. There were no virus treatmentrelated deaths or observable toxicity (activity or weight change) in these two animal tumor studies (Supplementary Figures S4c and d) . PBS-treated tumors showed a continuous increase in tumor growth. Treatment with HYPR-Ad#1 and HYPR-Ad-IL4 did not reduce tumor growth (P40.087). By contrast, HIF-Ad and HIF-Ad-IL4 treatments inhibited tumor growth even at the low viral dose used. HIF-Ad treatment at the 5 Â 10 7 IFU dose led to a significant 1.8-to 3.2-fold decrease in tumor growth compared with PBS-and HYPR-Ad#1-treated tumors from day 49 to day 64 of the study (Figure 5c , Po0.039). These results show that the augmented replication and cytolytic activity of HIF-Ad measured in vitro translated into an improved antitumor response. HIF-Ad-IL4 treatment resulted in a significant 1.5-to 2.3-fold decrease in tumor growth compared with PBS-and HYPR-Ad-IL4-treated tumors from day 52 to day 73 of the study (Figure 5d, Po0.005) . The HIF-Ad-IL4 versus HYPR-Ad-IL4 study was repeated with similar findings (not shown). However, treatment with HIF-Ad at the 5 Â 10 6 IFU dose did not reduce tumor growth (Supplementary Figure 5) . These results indicate that the observed antitumor response of HIF-Ad-IL4 at the 1 Â 10 6 IFU dose is most likely due to expression of the IL4 therapeutic gene rather than the cytolytic activity of the virus. In summary, these results show that the antitumor activity of the HIF-Ads is superior to the HYPR-Ads.
To better understand the potent antitumor effects of HIF-Ad-IL4 compared with HIF-Ad and HYPR-Ad-IL4, we examined intratumoral IL4 levels and tumor infiltration by CD45+ leukocytes (Figure 6 ). Intratumoral IL4 levels were measured in LN229 tumors treated with HYPR-Ad-IL4 or HIF-Ad-IL4 (Figure 6a ). HIF-Ad-IL4-treated tumors showed a significant 2-and 27-fold increase in intratumoral IL4 levels compared with HYPR-Ad-IL4-treated tumors at days 4 and 10 after treatment, respectively (Po0.018). In an independent experiment, we included HIF-Ad treatment for comparison (Figure 6b ). In this study, tumors treated with HIFAd-IL4 showed a 9-to 10-fold increase in intratumoral IL4 levels compared with HIF-Ad-and HYPR-Ad-IL4-treated tumors at day 11 after treatment (Po0.033). Importantly, there was no difference in intratumoral IL4 levels between HIF-Ad-and HYPR-Ad-IL4-treated tumors (P ¼ 0.976). CD45 leukocyte common antigen immunostaining showed that HIF-Ad-IL4-treated tumors contained extensive tumor infiltration by CD45+ leukocytes (Figure 6c ). By contrast, PBS-and HIF-Ad-treated tumors contained CD45+ leukocytes, but the degree of infiltrate was substantially less compared with the HIF-Ad-IL4-treated tumor (Figure 6c ). Hematoxylin and eosin (H&E) staining showed that HIFAd-IL4 treatment leads to widespread immune cell infiltration and tumor necrosis, with little viable tumor remaining (Figure 6c ). By contrast, H&E staining of PBS-and HIF-Ad-treated tumors showed mostly viable tumor (Figure 6c ). PBS-treated tumors had no necrosis whereas HIF-Ad-treated tumors showed a small number of isolated necrotic pockets. These results show that HIF-Ad-IL4 expresses high levels of IL4 in treated tumors and this correlates with massive tumor infiltration by CD45+ leukocytes and tumor cell necrosis.
Discussion
The results show that we have successfully created two second-generation HIF-activated Ads, HIF-Ad and HIF-Ad-IL4, that have enhanced oncolytic properties. The use of an alternative Ad cloning system enabled the introduction of two key alterations in HIF-Ad and HIF-Ad-IL4: (i) a modified HIF-responsive promoter to enhance virus replication and (ii) insertion of the E3 gene region to enhance the spread of the virus through the tumor. As a result HIF-Ad and HIF-Ad-IL4 have robust hypoxia/HIF-dependent E1A and IL4 expression, replication, cellular release and oncolytic activity. In addition, these viruses have antitumor activity. Most importantly, the HIF-Ads have significantly increased replication, cellular release, oncolytic and antitumor activity compared with the first-generation HYPR-Ad series of HIF-activated oncolytic Ads. These studies show the increased potency of the HIF-Ads for cancer therapy.
We were the first to describe the use of a bi-directional promoter to simultaneously regulate the expression of E1A and a therapeutic transgene in an oncolytic Ad.
28,31
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The bi-directional HIF-responsive promoter that we designed is unique and offers several advantages compared with other promoters. First, the size of the promoter is relatively small. Second, the promoter is bi-directional. These features allow us introduce the exogenous promoter and a therapeutic transgene without the need to delete important viral genes, such as those in the E3 gene region. An alternative strategy is to incorporate large exogenous promoters and/or therapeutic transgenes after complete or partial deletion of the E3 gene region. 19, [40] [41] [42] One drawback to this approach is accelerated virus clearance by the host immune response in vivo. 43 A third important feature of our HIF-responsive promoter is that it is not inhibited during the Ad replication cycle (Figure 1 ). E1A can bind to the p300 transcriptional coactivator resulting in an inhibition of HIF-dependent gene expression. 32, 33 However, a number of HIF-target genes are still activated in the absence of p300. 44 Given the complex regulation of HIF transcriptional activity, 45 it is possible that the specific configuration of our HIF-responsive promoter confers a p300-independent activation mechanism. Alternatively, the ability of E1A to abrogate HIF-dependent gene expression may be dependent on the E1A and/or p300 levels that are present in a particular model or experimental condition. A fourth advantage of our HIFresponsive promoter is its ability to retain selective activation in response to hypoxia after its incorporation into the Ad genome (Figure 2) . By contrast, an alternative HIF-responsive promoter lost its hypoxia-dependent regulation when introduced into the Ad genome. 46 Finally, our results show the HIF-Ads expressed similar E1A levels under hypoxia compared to a wild-type Ad (Figure 2b and Supplementary Figure S1a) . This shows that the transcriptional strength of the HIF-responsive promoter present within the HIF-Ads is similar to the endogenous E1A promoter of a wild-type Ad. Consistent with this, the levels of E1A induced under hypoxia efficiently activate the HIF-Ad replication cycle ( Figures  4a and b, and Supplementary Figure S1e) . This results in extensive killing of hypoxic, but not normoxic, tumor cells in culture (Figure 3 and Supplementary Figure S1d ) and antitumor activity in vivo ( Figure 5 ). These features of HIF-Ad are important as hypoxia can negatively effect the replication and oncolytic efficacy of wild-type Ads in culture. 47, 48 The rationale for improving HIF-activated oncolytic Ad therapy is that increased viral progeny production (replication) and cell-to-cell spread (oncolysis and cellular release) will result in a more potent antitumor response. Our results show that HIF-Ad has significantly improved replication, cytolysis and cellular release compared with HYPR-Ad#1 in vitro and this leads to in an improved antitumor response in vivo. Our data also show increased expression of the IL4 transgene by HIF-Ad-IL4 compared with HYPR-Ad-IL4 in vitro and in vivo. These results are most likely due to increased replication of HIF-Ad-IL4 rather than differences in the Improved HIF-activated oncolytic adenoviruses T Cherry et al strength of the HIF-responsive promoters. In support of this are the E1A expression and virus replication studies (Figures 2 and 4) . To further investigate this, it will be important to conduct detailed in vivo viral replication and E1A and IL4 expression studies after HYPR-Ad#1, HIF-Ad, HYPR-Ad-IL4 and HIF-Ad-IL4 treatments.
The IL4 cytokine has multimodal antitumor activity associated with its ability to induce a host antitumor immune response, inhibit tumor angiogenesis and inhibit tumor cell proliferation. 30 Our studies show the potent antitumor effect of IL4 when locally delivered to the tumor microenvironment by an oncolytic Ad. Furthermore, we show that the intrinsic oncolytic effect of HIF-Ad and the actions of the IL4 transgene are important components of the antitumor effect. The data also suggest that the antitumor effects of IL4 are stronger than the oncolytic activity of the virus. Now that we have established the antitumor efficacy of HIF-Ad and HIF-Ad-IL4 it will be important to better understand the mechanism(s) underlying the potent antitumor response induced by IL4. Here we show that HIF-Ad-IL4 treatment is associated with extensive infiltration of the tumor mass with CD45+ leukocytes. A next useful study will be to identify and quantify the specific immune cell types, which are infiltrating the tumors in response to IL4 expression versus oncolytic Ad treatment. Once this is defined, we can determine the role of the host immune response in the antitumor activity of HIF-Ad-IL4. In addition to gaining a better understanding of how IL4 modulates host immune responses, we can also explore whether IL4 induces an antiangiogenic response in our tumor models. This may be particularly advantageous for HIF-Ad treatment because it would generate hypoxia/HIF activation in the tumor mass, thereby creating a positive feedback loop leading to increased activation of the virus. Finally, additional antitumor efficacy studies using recently identified syngeneic rodent tumor models that support human Ad replication will be highly beneficial. [49] [50] [51] [52] These tumor models use immunocompetent rodents that have a fully functional immune system and therefore will enable us to evaluate T-and B-cell responses during HIF-Ad treatment. However, use of IL4 for cancer therapy is controversial because it may not support a strong, longterm immunity mediated by CD8+ cytolytic T-lymphocytes. Conversely, the ability of IL4 to suppress a Th1 type antiviral immune response mediated by cytolytic T-lymphocytes may be beneficial for HIF-Ad therapy by reducing virus clearance. [53] [54] [55] This may lead to prolonged intratumoral virus replication and greater tumor cell death. Regardless of the mechanism, our studies with HIF-Ad-IL4 and published studies on IL4 treatment of experimental tumors show that IL4 can induce regressions in tumor size and tumor eradication. 31, 56, 57 This justifies the continued pursuit of the IL4 cytokine for cancer therapy.
Our results show that the replication and oncolytic efficacy of the HIF-activated oncolytic Ads has been increased without compromising tumor specificity. For comparison, we used a wild-type Ad (Ad5WT), which is not tumor-selective and therefore cannot be used in a clinical setting due to widespread toxicity to normal, healthy cells. We found that the HIF-Ads have hypoxia-dependent replication, which is similar to or slightly reduced compared with Ad5WT. In addition, the HIF-Ads induced hypoxia-dependent cytotoxicity at a rate and magnitude that was indistinguishable from that of Ad5WT. Finally, the HIF-Ads showed antitumor activity, which was similar to or greater than that of Ad5WT. In the case of large tumors, the antitumor efficacy of HIF-Ad-IL4 was superior to that of Ad5WT. Most importantly, the antitumor activity of HIF-activated oncolytic Ad treatment was improved without increasing general toxicity (changes in animal weight or behavior). By contrast, an oncolytic Ad, which expresses IL12 (induces a classical Th1 type immune response), caused toxicity in rodents, which required a reduction in the viral dose for in vivo studies. 58 Toxicity was due to IL12 expression and not viral replication. Our in vivo studies with HIF-Ad-IL4 show that therapeutically efficacious levels of IL4 can be achieved and these cytokine levels do not cause obvious signs of toxicity in treated rodents compared with PBS or HIF-Ad treatment. The next step is to undertake extensive safety and toxicity studies of the HIF-Ads in vivo using permissive animal models. Recently, the ability of the cotton rat 59 and Syrian golden hamster 60 to support human Ad replication was shown. Use of these animal models will allow us to better evaluate if the HIF-Ads replicate in a particular organ/ tissue or under certain in vivo conditions. Collectively, our data show that we have developed a potent and efficacious HIF-activated oncolytic Ad for the treatment of hypoxic tumor cells. As hypoxia is a hallmark of tumor growth and progression, the HIF-Ads can be used as a treatment for a wide range of primary and metastatic tumors regardless of tissue origin or genetic mutations in oncogene and tumorsuppressor gene pathways.
Materials and methods
Construction of HIF-Ad and HIF-Ad-IL4, Ads, and cells HIF-Ad and HIF-Ad-IL4 were created using the pE1.1 and pAd329 vectors (OD260, Inc., Boise, ID). To generate HIF-Ad, an 884-bp SpeI/StuI fragment from pBI-V6R 27 was ligated into the shuttle vector pE1.1 digested with XbaI/EcoRV, creating pE1.1-V6R. pE1.1-V6R was digested with DraIII and ligated into the SfiI pre-digested pAd329 vector, creating pAd-V6R. To generate HIF-Ad-IL4, a 1326-bp SpeI/StuI fragment from pBI-V6R-IL4 31 was ligated into pE1.1 digested with XbaI/EcoRV, creating pE1.1-V6R-IL4. pE1.1-V6R-IL4 was digested with DraIII and ligated into the SfiI pre-digested pAd329 vector, creating pAd-V6R-IL4. To create recombinant HIF-Ad and HIF-Ad-IL4 viruses, pAd-V6R and pAd-V6R-IL4 were transferred into Escherichia coli by means of packaging into phage l to create pAd cosmids. pAd cosmids were linearized with PacI and then purified using the Qiaex II kit (Qiagen, Valencia, CA, USA). Ad293 packaging cells were transfected with a linearized pAd cosmid using lipofectamine (Invitrogen, Carlsbad, CA, USA) and then incubated in a standard cell culture incubator until viral plaques were observed (8-9 days). Virus was recovered from cells by three freeze-thaw cycles.
AdLacZ is a replication-deficient, Ad which lacks the E1 gene region and expresses LacZ (UNC Virus Vector Core Facility, Chapel Hill, NC, USA). Ad5WT is a replication-competent Ad, which contains a wild-type ) and U251MG-T2 (1.25 Â 10 5 ) cells were transfected with 1 mg pBIGL-V6R using the GenePORTER transfection reagent (Genlantis, San Diego, CA, USA) as described by Post and Van Meir. 27 pBIGL-V6R contains the luciferase reporter gene under the control of an HIF-responsive promoter. The next day, cells were mock-or virusinfected with a wild-type Ad (dl309-Ad; UNC Virus Vector Core Facility) in triplicate. LN229 cells were infected at MOI 1, 5 and 25 whereas U251MG cells were infected at MOI 0.0625, 0.25 and 1. Cells were placed under normoxia versus hypoxia. One day later luciferase activity was measured using a Luc-screen kit (Applied Biosystems, Foster City, CA, USA) and normalized to total cellular protein (light units/mg protein).
E1A and IL4 expression
LN229 and Daoy cells were mock-or virus-infected at MOI 1. The cells were placed under normoxia versus hypoxia. E1A expression was examined by western blot analysis. Cells were collected in PBS using a cell scraper and then pelleted by microcentrifugation for 5 min at 2300 Â g. The collected cells were lysed using a lysing buffer (20 mM sodium phosphate, 5 mM EDTA, 150 mM NaCl, 50 mM NaF, 1% Triton X-100, 1 Â protease inhibitor cocktail and 1 Â phosphatase inhibitor cocktail (Sigma, St Louis, MO, USA)). Protein concentrations were determined using Protein Assay Dye (Bio-Rad, Hercules, CA, USA). Proteins (15 or 20 mg) were separated by electrophoresis using 10% Criterion Precast gels (Bio-Rad) and blotted to a polyvinylidene difluoride membrane (Bio-Rad). The primary antibody used was anti-E1A (Adenovirus Ab-5 cocktail; NeoMarkers, Fremont, CA, USA). The secondary antibody was an anti-mouse IgG+IgM alkaline phosphate-linked whole antibody from goat (Amersham Biosciences, Piscataway, NJ, USA). Signal was detected using an ECF substrate (Amersham Biosciences). The membrane was stripped of signal using 1 Â Stripping buffer (Boston BioProducts, Worcester, MA, USA) and then re-probed with the primary antibody anti-GAPDH (Calbiochem, La Jolla, CA, USA) as a loading control. IL4 protein levels were quantified by ELISA (Pierce, Rockford, IL, USA) using conditioned media collected from in vitro studies or tumor homogenates from in vivo studies. For intratumoral IL4 expression studies, LN229 cells (7.5 Â 10 6 cells in 200 ml PBS) were implanted subcutaneously into the flanks of nu/nu mice (athymic NCr-nu; NCI, Frederick, MD, USA). As shown in Figure 6a , tumors were established to an average size of 223 mm 3 and then injected intratumorally with 5 Â 10 5 IFU of HIF-Ad-IL4 or HYPR-Ad-IL4 diluted in PBS (0.1 ml total injection volume). Tumors (n ¼ 5 mice/group) were collected on days 4 and 10 after treatment. In Figure 6b , tumors were established to an average size of 132 mm 3 and then injected intratumorally with 5 Â 10 5 IFUs of HIF-Ad, HIFAd-IL4 or HYPR-Ad-IL4. Tumors (n ¼ 6 mice/group) were collected at day 11 after treatment. The collected tumors were homogenized in 0.75 ml PBS, sonicated for 1 min, centrifuged for 5 min at 16 000 Â g at 4 1C and the cleared supernatant was used for ELISA. Intratumoral IL4 levels were normalized to total protein levels (Protein Assay Dye, Bio-Rad) of the cleared tumor homogenates.
Tumor cell lysis assays
For CPE assays, LN229 cells were infected at MOI 10 and 25; U251MG-T2 cells were infected at MOI 0.25, 1 and 3; and Daoy cells were infected at MOI 5. For MTT assays LN229 cells were infected at MOI 25 whereas U251MG-T2 cells were infected at MOI 0.25 and 1.0 in triplicate. For lactate dehydrogenase (LDH) assays, LN229 cells were infected at MOI 25 whereas Daoy cells were infected at MOI 1 in triplicate. After infection, cells were placed under normoxia versus hypoxia. Cells were visually monitored for CPE (cell lysis/detachment) and then analyzed when extensive CPE was seen in HIF-Ad/HIF-Ad-IL4-infected cells under hypoxia. For CPE assays, the cells were fixed with ice-cold 100% methanol, stained with crystal violet solution (1% crystal violet, 10% formaldehyde, 20% ethanol, in water) for 20 min, destained in water and allowed to dry at room temperature. Photographs were taken at Â 100 magnification. CPE was quantified by an MTT assay. Cytotoxicity was quantified by an LDH assay (Cytotoxicity Detection Kit; Roche Applied Science, Indianapolis, IN, USA). For the MTT and LDH assays, the values obtained with virus infection were normalized to those from mock-infected cells.
Viral replication and cellular release assays
LN229 and Daoy cells were infected with virus at MOI 1 in triplicate. The cells were placed under normoxia versus hypoxia. For the viral replication assay, cells were collected in PBS using a cell scraper and pelleted by microcentrifugation for 5 min at 16 000 Â g. Cell pellets were resuspended in serum-free Dulbecco's Modified Eagle's Medium and virus was released from the cells by three freeze-thaw cycles. Cellular debris was removed by microcentrifugation and the virus-containing supernatant was titered as described by Post et al. 31 For the cellular release assay, conditioned media was collected and titered.
Antitumor efficacy studies LN229 cells (7.5 Â 10 6 cells in 200 ml PBS) were implanted subcutaneously into the flanks of nu/nu mice (athymic NCr-nu; NCI; day 1 of the study). As shown in Figure 5a 
H&E and CD45+ leukocyte analysis of tumors
Subcutaneous LN229 tumors in nu/nu mice were treated with PBS or 1 Â 10 7 IFUs of HIF-Ad or HIF-Ad-IL4 at days 35 and 39 after tumor cell implantation. On day 49, tumors were harvested and processed for sectioning as described by Post et al. 31 Tumor sections were stained with H&E and immunostained for CD45 leukocyte common antigen, a pan leukocyte marker, as described by Post et al.
31
Statistical analysis ELISA, MTT, LDH, viral replication and cellular release data were analyzed using a Student's t-test. In the tumor studies shown in Figures 5a-d 
